DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Clinical Trial of Lithium Carbonate Combined With Neo-adjuvant Chemotherapy to Treat Osteosarcoma

Information source: Sun Yat-sen University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Osteosarcoma

Intervention: Lithium Carbonate (Drug)

Phase: Phase 4

Status: Recruiting

Sponsored by: Sun Yat-sen University

Official(s) and/or principal investigator(s):
Jin Wang, PhD, Principal Investigator, Affiliation: First Affiliated Hospital, Sun Yat-Sen University

Overall contact:
Jin Wang, PhD, Phone: +86-20-87755766, Ext: 8236, Email: 2004wjhf@163.com

Summary

The purpose of this study is to determine whether Lithium Carbonate combined with neo-adjuvant chemotherapy improve the prognosis of osteosarcoma

Clinical Details

Official title: A Prospected Randomized Multicenter Clinical Trial of Lithium Carbonate Combined With Neo-adjuvant Chemotherapy to Treat Osteosarcoma

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: progression-free survival,incidence of chemotherapy-induced myelosuppression

Secondary outcome: over-all survival,metastasis-free survival

Detailed description: Osteosarcoma is the most common primary malignant bone tumor in childhood and adolescence, the prognosis for the disease is poor. What's more, chemotherapy resistance and serious myelosuppression occur frequently in clinical further hindered canonical adjuvant chemotherapy. In our previous researches, we observed that GSK-3B positively regulates the NF-kB pathway to promote proliferation and tumorigenicity in osteosarcoma cell. Targeted inhibition of GSK3beta showed an obvious antitumor effect. It is a promising therapeutic target in osteosarcoma, especially if GSK-3b inhibition is combined with chemotherapeutic drugs. Lithium carbonate, commonly use in clinical application because of its fine quality and cheap price, was proven to be effected as a kind of GSK3beta inhibitor and stimulating factor of peripheral blood leukocyte. Therefore, lithium carbonate theoretically possesses effects of both anti-tumor as well as improvement of myelosuppression. We look forward to the results of clinical trials to test the effect of combinations of chemical drugs with lithium carbonate on myelosuppression, disease-free survival rate and lung metastasis rate in patients with osteosarcoma who treated with conventional chemotherapeutic regimens and wide resection. This study is a multi-centre, double-blind, randomized clinical trial phase 4. The inclusion criterion is patients with primary osteosarcoma in femur, tibia and humerus(IIB). With the help of statistic method, 400 patients were randomly divided into two groups according to sequence of entering the group: lithium carbonate group and control group (1: 1). Patients were suggesting continuing this trial until the end of the chemotherapy regimen or being confirmed as disease progression by RECIST guiding principles. According to their histological types, patients are analyzed using subgroup analysis. Disease evaluation will be conducted every 8 weeks. A follow-up to count the overall survival rate after grouping was performed within at least 24 months or at most 120 months. Our study may represent a novel and feasible approach by combination of conventional chemotherapy drugs and targeted drugs. More importantly, it may hopefully be a promising strategy to improve overall survival of osteosarcoma.

Eligibility

Minimum age: 8 Years. Maximum age: 70 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- histologically diagnosed primary classical osteosarcoma in extremities

- staging IIB

- MRI showing no skip lesion

- receive standard neo-adjuvant chemotherapy, adjuvant chemotherapy,and standard

surgical treatment Exclusion Criteria:

- a history of non-standard treatment(chemotherapy or surgery)

- secondary osteosarcoma or well-differentiated parosteal osteosarcoma

- evident dysfunction of cardia,liver and kidney, or pregnant women or women during

lactation

Locations and Contacts

Jin Wang, PhD, Phone: +86-20-87755766, Ext: 8236, Email: 2004wjhf@163.com

The first affiliated hospital,Sun Yat-sen University, Guangzhou, Guangdong 510080, China; Recruiting
Jin Wang, PhD, Phone: +86-87755766, Ext: 8236, Email: 2004wjhf@163.com;viewrine@qq.com
Jin Wang, PhD, Principal Investigator

The first affiliated hospital,Sun Yat-sen University, Guangzhou, Guangdong 510080, China; Not yet recruiting
Jin Wang, PhD, Phone: +86-20-87755766, Ext: 8236

Additional Information

Starting date: January 2013
Last updated: December 1, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017